Special Issue "Research Advances and Therapeutic Strategies of Human Osteosarcoma"
Deadline for manuscript submissions: 15 July 2020.
Interests: primary bone tumors; RANKL/RANK/OPG signaling; tumor microenvironment; metastases; drug resistance; therapies
Interests: bone sarcoma; Wnt signaling; metastases; tumor microenvironment
Interests: sarcoma; circulating tumor cells; dormancy; drug resistance; microenvironment; microfluidics
Osteosarcoma is the most frequent pediatric primary bone tumor. Current treatments that combine conventional chemotherapies and surgery have enabled to reach a five-year remission rate higher than 70%. However, this rate dramatically decreases below 30% if metastases are observed at the time of diagnosis or if the tumor is resistant to chemotherapy. In the last decade, besides researches on new therapeutic targets to eradicate the tumor cells (epigenetic, genetic, or metabolic targets), many studies have been devoted to a better understanding of both metastatic and resistance processes in order to be able, in a near future, to block or reverse them. These studies have mainly focused on the tumor microenvironment and on tumor cell heterogeneity in those two processes.
This Special Issue will discuss recent developments in our understanding of osteosarcoma metastatic and resistance processes and delineate future therapies based on the blockage of these two deleterious processes.
Dr. Frédéric Lézot
Dr. Bénédicte Brounais-Le-Royer
Prof. Dominique Heymann
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.